Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Morrison & Foerster helped secure a $775 million patent litigation settlement for its client, Chugai Pharmaceutical Co., Ltd., for Alexion Pharmaceuticals, Inc.’s sales of the anti-complement antibody product, ULTOMORIS® (ravulizumab).



Morrison & Foerster Secures $775M Patent Settlement for Client Chugai

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Morrison & Foerster helped secure a $775 million patent litigation settlement for its client, Chugai Pharmaceutical Co., Ltd., for Alexion Pharmaceuticals, Inc.’s sales of the anti-complement antibody product, ULTOMORIS® (ravulizumab).Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. The patents-at-issue in the litigation claim methods of using recycling antibodies to bind to an antigen multiple times, allowing patients to be dosed less frequently than when using conventional antibodies.A jury trial was scheduled to begin in the U.S. District Court for the District of Delaware on February 14, but the parties filed a motion that morning to stay the case pending finalization of a settlement agreement. In addition to the settlement payment and in accordance with the settlement agreement, Chugai and Alexion are in the process of withdrawing patent infringement proceedings in the United States (U.S. Patent No. 9,890,377 and No. 10,472,623) and elsewhere in the world.  The Morrison & Foerster team representing Chugai was led by intellectual property litigation and trial partners Eric Acker, Brian Kramer, and Akira Irie, and appellate partner, Brian Matsui.

Morrison & Foerster Secures $775M Patent Settlement for Client Chugai

Sign Up

Eric M. Acker

Partner

Brian M. Kramer

Akira Irie

Brian R. Matsui

Life Sciences + Healthcare

Litigation

Patent Litigation

Japan